Geoffrey L. Uy

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2018 · 990 citations · Full text

Medicine, Oncology, Pharmacology +15

<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

John S. Welch, Allegra A. Petti, Christopher A. Miller et al. · New England Journal of Medicine · 2016 · 784 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +17

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

Bruno Nervi, Pablo Ramírez, Michael P. Rettig et al. · Blood · 2008 · 481 citations · Full text

Medicine, Oncology, Pharmacology +13

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

Geoffrey L. Uy, Michael P. Rettig, Ibraheem Motabi et al. · Blood · 2012 · 388 citations · Full text

Medicine, Oncology, Pharmacology +15